GlassScriptPhysician profile
Philip Koi
NPI 1740324912
$13,929.74
in general payments reported to CMS, 2019-2025
51 companies · $2,541 in 2025
The $2,541 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $511 · 2021: $1,378 · 2022: $2,956 · 2023: $2,596 · 2024: $2,724 · 2025: $2,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,271 · Travel and Lodging: $456 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,270.96 |
| Travel and Lodging | $455.84 |
| Education | $135.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,715.81 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $1,206.61 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Medtronic, INC. | $1,107.28 | 2021-2025 | Interstim |
| Boston Scientific Corporation | $1,101.96 | 2019-2024 | Rezum Generator, Solyx Sis System, Ams 700 Cxr Rte Kit |
| Janssen Biotech, INC. | $924.44 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Pfizer INC. | $757.94 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $652.67 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $651.28 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $575.19 | 2021-2025 | Prolaris |
| Abbvie INC. | $514.50 | 2019-2025 | |
| Procept Biorobotics Corporation | $423.84 | 2022-2025 | Aquabeam Robotic System |
| Dendreon Pharmaceuticals LLC | $403.61 | 2019-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $368.44 | 2021-2025 | |
| Antares Pharma, INC. | $365.14 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Tolmar, INC. | $318.61 | 2023-2025 | Eligard |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Koi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.